This study demonstrated that ovarian cancer patients with mutated BRCA1/2 had a four-fold increased risk of developing brain metastases and were diagnosed with brain metastases approximately 8 months earlier than patients with wild-type BRCA1/2 [46]. This evidence concerns the gene BRCA1 and ovarian carcinoma.